UCB Share Price Other OTC
Stocks
UCBJF
BE0003739530
Pharmaceuticals
OTC Markets Traded
| Market Cap | 47.53B 54.51B 43.98B 41.19B 77.12B 5,143B 77.71B 523B 202B 2,531B 205B 200B 8,794B | P/E 2026 * |
26.9x | P/E 2027 * | 20.7x |
|---|---|---|---|---|---|
| Enterprise Value | 46.43B 53.24B 42.95B 40.23B 75.33B 5,023B 75.9B 510B 198B 2,472B 200B 196B 8,589B | EV / Sales 2026 * |
5.45x | EV / Sales 2027 * | 4.61x |
| Free-Float |
61.59% | Yield 2026 * |
0.59% | Yield 2027 * | 0.6% |
Last Transcript: UCB
| 1 day | -0.39% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 31/12/2014 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 59 | 30/06/2020 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 30/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 31/12/2011 | |
| Director/Board Member | 67 | 31/12/2014 | |
| Director/Board Member | 56 | 23/04/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.39% | -.--% | - | - | 54.52B | |
| +0.33% | -0.36% | +18.76% | -22.11% | 62.05B | |
| -3.92% | +37.40% | +37.40% | +37.40% | 41.55B | |
| +7.62% | +8.19% | -51.27% | -59.11% | 39.06B | |
| -1.05% | -1.73% | +55.35% | -33.92% | 29.02B | |
| +3.50% | +28.15% | +151.81% | -50.31% | 25.38B | |
| -0.78% | -9.50% | +43.87% | +55.34% | 19.62B | |
| +1.74% | -0.39% | -2.93% | +113.90% | 16.89B | |
| -0.05% | +0.23% | +61.48% | +101.93% | 15.89B | |
| -1.66% | -0.79% | +65.68% | +341.51% | 12.98B | |
| Average | +0.53% | +3.58% | +42.24% | +53.85% | 29.16B | |
| Weighted average by Cap. | +0.58% | +3.81% | +33.59% | +17.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.53B 9.78B 7.89B 7.39B 13.83B 922B 13.94B 93.72B 36.29B 454B 36.7B 35.91B 1,577B | 9.65B 11.07B 8.93B 8.36B 15.66B 1,044B 15.78B 106B 41.07B 514B 41.54B 40.65B 1,785B |
| Net income | 1.74B 1.99B 1.61B 1.51B 2.82B 188B 2.84B 19.12B 7.4B 92.63B 7.49B 7.33B 322B | 2.31B 2.65B 2.14B 2B 3.75B 250B 3.78B 25.39B 9.83B 123B 9.94B 9.73B 427B |
| Net Debt | -1.11B -1.27B -1.02B -960M -1.8B -120B -1.81B -12.17B -4.71B -58.96B -4.77B -4.66B -205B | -3.07B -3.52B -2.84B -2.66B -4.98B -332B -5.01B -33.71B -13.05B -163B -13.2B -12.92B -567B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
